PEGylation of Linkers Improves Antitumor Activity and Reduces Toxicity of Immunoconjugates
Description of Invention:
The present invention relates to site-directed PEGylation of immunoconjugates. In particular, it provides a new approach for modifying with polyethylene glycol (PEG) a connector molecule that attaches the toxin moiety to the targeting moiety of an immunotoxin. The PEGylated immunotoxin has comparable in vitro specific toxicity against tumor cells, but other properties including stability, plasma half-life, antitumor activity, immunogenicity and non-specific toxicity are greatly improved.
The application contains composition of matter claims towards PEGylated connector molecules and method claims for using said PEGylated connector molecules.
Inventors:
I. Pastan (NCI) Y. Tsutsumi (NCI) M. Onda (NCI) S. Nagata (NCI) B. Lee (NCI)
